Nanofluidic microsystem for sustained intraocular delivery of therapeutics

Research output: Contribution to journalArticle

Nicola Di Trani, Priya Jain, Corrine Ying Xuan Chua, Jeremy S Ho, Giacomo Bruno, Antonia Susnjar, Fernanda Paola Pons-Faudoa, Antons Sizovs, R Lyle Hood, Zachary W Smith, Andrea Ballerini, Carly S Filgueira, Alessandro Grattoni

Globally, 145.2 million people suffer from moderate to severe vision impairment or blindness due to preventable or treatable causes. However, patient adherence to topical or intravitreal treatment is a leading cause of poor outcomes. To address this issue, we designed an intraocularly implantable device called the nanofluidic Vitreal System for Therapeutic Administration (nViSTA) for continuous and controlled drug release based on a nanochannel membrane that obviates the need for pumps or actuation. In vitro release analysis demonstrated that our device achieves sustained release of bimatoprost (BIM) and dexamethasone (DEX) at concentrations within clinically relevant therapeutic window. In this proof of concept study, we constructed an anatomically similar in silico human eye model to simulate DEX release from our implant and gain insight into intraocular pharmacokinetics profile. Overall, our drug-agnostic intraocular implant represents a potentially viable platform for long-term treatment of various chronic ophthalmologic diseases, including diabetic macular edema and uveitis.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume16
Early online dateNov 20 2018
DOIs
StatePublished - Feb 1 2019

PMID: 30468870

Altmetrics

Cite this

Standard

Nanofluidic microsystem for sustained intraocular delivery of therapeutics. / Di Trani, Nicola; Jain, Priya; Chua, Corrine Ying Xuan; Ho, Jeremy S; Bruno, Giacomo; Susnjar, Antonia; Pons-Faudoa, Fernanda Paola; Sizovs, Antons; Lyle Hood, R; Smith, Zachary W; Ballerini, Andrea; Filgueira, Carly S; Grattoni, Alessandro.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 16, 01.02.2019, p. 1-9.

Research output: Contribution to journalArticle

Harvard

Di Trani, N, Jain, P, Chua, CYX, Ho, JS, Bruno, G, Susnjar, A, Pons-Faudoa, FP, Sizovs, A, Lyle Hood, R, Smith, ZW, Ballerini, A, Filgueira, CS & Grattoni, A 2019, 'Nanofluidic microsystem for sustained intraocular delivery of therapeutics' Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 16, pp. 1-9. https://doi.org/10.1016/j.nano.2018.11.002

APA

Di Trani, N., Jain, P., Chua, C. Y. X., Ho, J. S., Bruno, G., Susnjar, A., ... Grattoni, A. (2019). Nanofluidic microsystem for sustained intraocular delivery of therapeutics. Nanomedicine: Nanotechnology, Biology, and Medicine, 16, 1-9. https://doi.org/10.1016/j.nano.2018.11.002

Vancouver

Di Trani N, Jain P, Chua CYX, Ho JS, Bruno G, Susnjar A et al. Nanofluidic microsystem for sustained intraocular delivery of therapeutics. Nanomedicine: Nanotechnology, Biology, and Medicine. 2019 Feb 1;16:1-9. https://doi.org/10.1016/j.nano.2018.11.002

Author

Di Trani, Nicola ; Jain, Priya ; Chua, Corrine Ying Xuan ; Ho, Jeremy S ; Bruno, Giacomo ; Susnjar, Antonia ; Pons-Faudoa, Fernanda Paola ; Sizovs, Antons ; Lyle Hood, R ; Smith, Zachary W ; Ballerini, Andrea ; Filgueira, Carly S ; Grattoni, Alessandro. / Nanofluidic microsystem for sustained intraocular delivery of therapeutics. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2019 ; Vol. 16. pp. 1-9.

BibTeX

@article{5295951c70e848ca9ccabc1e3d22dc9e,
title = "Nanofluidic microsystem for sustained intraocular delivery of therapeutics",
abstract = "Globally, 145.2 million people suffer from moderate to severe vision impairment or blindness due to preventable or treatable causes. However, patient adherence to topical or intravitreal treatment is a leading cause of poor outcomes. To address this issue, we designed an intraocularly implantable device called the nanofluidic Vitreal System for Therapeutic Administration (nViSTA) for continuous and controlled drug release based on a nanochannel membrane that obviates the need for pumps or actuation. In vitro release analysis demonstrated that our device achieves sustained release of bimatoprost (BIM) and dexamethasone (DEX) at concentrations within clinically relevant therapeutic window. In this proof of concept study, we constructed an anatomically similar in silico human eye model to simulate DEX release from our implant and gain insight into intraocular pharmacokinetics profile. Overall, our drug-agnostic intraocular implant represents a potentially viable platform for long-term treatment of various chronic ophthalmologic diseases, including diabetic macular edema and uveitis.",
keywords = "Diabetic macular edema, Intraocular implants, Microelectromechanical systems/nanoelectromechanical systems (MEMS/NEMS), Nanochannel diffusion, Uveitis",
author = "{Di Trani}, Nicola and Priya Jain and Chua, {Corrine Ying Xuan} and Ho, {Jeremy S} and Giacomo Bruno and Antonia Susnjar and Pons-Faudoa, {Fernanda Paola} and Antons Sizovs and {Lyle Hood}, R and Smith, {Zachary W} and Andrea Ballerini and Filgueira, {Carly S} and Alessandro Grattoni",
note = "Copyright {\circledC} 2018. Published by Elsevier Inc.",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.nano.2018.11.002",
language = "English (US)",
volume = "16",
pages = "1--9",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Nanofluidic microsystem for sustained intraocular delivery of therapeutics

AU - Di Trani, Nicola

AU - Jain, Priya

AU - Chua, Corrine Ying Xuan

AU - Ho, Jeremy S

AU - Bruno, Giacomo

AU - Susnjar, Antonia

AU - Pons-Faudoa, Fernanda Paola

AU - Sizovs, Antons

AU - Lyle Hood, R

AU - Smith, Zachary W

AU - Ballerini, Andrea

AU - Filgueira, Carly S

AU - Grattoni, Alessandro

N1 - Copyright © 2018. Published by Elsevier Inc.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Globally, 145.2 million people suffer from moderate to severe vision impairment or blindness due to preventable or treatable causes. However, patient adherence to topical or intravitreal treatment is a leading cause of poor outcomes. To address this issue, we designed an intraocularly implantable device called the nanofluidic Vitreal System for Therapeutic Administration (nViSTA) for continuous and controlled drug release based on a nanochannel membrane that obviates the need for pumps or actuation. In vitro release analysis demonstrated that our device achieves sustained release of bimatoprost (BIM) and dexamethasone (DEX) at concentrations within clinically relevant therapeutic window. In this proof of concept study, we constructed an anatomically similar in silico human eye model to simulate DEX release from our implant and gain insight into intraocular pharmacokinetics profile. Overall, our drug-agnostic intraocular implant represents a potentially viable platform for long-term treatment of various chronic ophthalmologic diseases, including diabetic macular edema and uveitis.

AB - Globally, 145.2 million people suffer from moderate to severe vision impairment or blindness due to preventable or treatable causes. However, patient adherence to topical or intravitreal treatment is a leading cause of poor outcomes. To address this issue, we designed an intraocularly implantable device called the nanofluidic Vitreal System for Therapeutic Administration (nViSTA) for continuous and controlled drug release based on a nanochannel membrane that obviates the need for pumps or actuation. In vitro release analysis demonstrated that our device achieves sustained release of bimatoprost (BIM) and dexamethasone (DEX) at concentrations within clinically relevant therapeutic window. In this proof of concept study, we constructed an anatomically similar in silico human eye model to simulate DEX release from our implant and gain insight into intraocular pharmacokinetics profile. Overall, our drug-agnostic intraocular implant represents a potentially viable platform for long-term treatment of various chronic ophthalmologic diseases, including diabetic macular edema and uveitis.

KW - Diabetic macular edema

KW - Intraocular implants

KW - Microelectromechanical systems/nanoelectromechanical systems (MEMS/NEMS)

KW - Nanochannel diffusion

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=85058793474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058793474&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.11.002

DO - 10.1016/j.nano.2018.11.002

M3 - Article

VL - 16

SP - 1

EP - 9

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

T2 - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

ER -

ID: 42509672